Cargando…

The persistence of anti-Spike antibodies following two SARS-CoV-2 vaccine doses in patients on immunosuppressive therapy compared to healthy controls—a prospective cohort study

BACKGROUND: The durability of vaccine-induced humoral immunity against SARS-CoV-2 in patients with immune-mediated inflammatory diseases (IMIDs) on immunosuppressive therapy is not known. The aim of this study was to compare the persistence of anti-Spike antibodies following two-dose SARS-CoV-2 vacc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Christensen, Ingrid Egeland, Jyssum, Ingrid, Tveter, Anne Therese, Sexton, Joseph, Tran, Trung T., Mjaaland, Siri, Kro, Grete Birkeland, Kvien, Tore K., Warren, David John, Jahnsen, Jørgen, Munthe, Ludvig A., Haavardsholm, Espen A., Vaage, John Torgils, Grødeland, Gunnveig, Lund-Johansen, Fridtjof, Jørgensen, Kristin Kaasen, Syversen, Silje Watterdal, Goll, Guro Løvik, Provan, Sella Aarrestad
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9534475/ https://www.ncbi.nlm.nih.gov/pubmed/36199139 http://dx.doi.org/10.1186/s12916-022-02587-8

Ejemplares similares

Immunogenicity and safety of a three-dose SARS-CoV-2 vaccination strategy in patients with immune-mediated inflammatory diseases on immunosuppressive therapy
por: Syversen, Silje Watterdal, et al.
Publicado: (2022)

Four SARS-CoV-2 vaccine doses or hybrid immunity in patients on immunosuppressive therapies: a Norwegian cohort study
por: Bjørlykke, Kristin H, et al.
Publicado: (2023)

Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study
por: Jyssum, Ingrid, et al.
Publicado: (2022)

Immunogenicity and Safety of Standard and Third‐Dose SARS–CoV‐2 Vaccination in Patients Receiving Immunosuppressive Therapy
por: Syversen, Silje W., et al.
Publicado: (2022)

Sa1052: IMMUNOGENICITY AND SAFETY OF STANDARD AND THIRD DOSE SARS-COV-2 VACCINATION IN PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY DISEASES; A PROSPECTIVE COHORT STUDY
por: Joergensen, Kristin K., et al.
Publicado: (2022)

Hybrid and SARS-CoV-2-vaccine immunity in kidney transplant recipients
por: Kared, Hassen, et al.
Publicado: (2023)

Risk factors for anti‐drug antibody formation to infliximab: Secondary analyses of a randomised controlled trial
por: Brun, Marthe Kirkesæther, et al.
Publicado: (2022)

T cell responses to SARS-CoV-2 vaccination differ by disease-modifying therapy for multiple sclerosis
por: Wolf, Asia-Sophia, et al.
Publicado: (2023)

Immune response and safety in standard and third dose SARS-CoV-2 vaccination in patients with autoimmune hepatitis on immunosupressive therapy, a prospective cohort study
por: Jorgensen, Kristin, et al.
Publicado: (2022)

Assessing Immunogenicity of Biologic Drugs in Inflammatory Joint Diseases: Progress Towards Personalized Medicine
por: Gehin, Johanna Elin, et al.
Publicado: (2022)

Associations between certolizumab pegol serum levels, anti-drug antibodies and treatment response in patients with inflammatory joint diseases: data from the NOR-DMARD study
por: Gehin, Johanna Elin, et al.
Publicado: (2019)

Serum etanercept concentrations in relation to disease activity and treatment response assessed by ultrasound, biomarkers and clinical disease activity scores: results from a prospective observational study of patients with rheumatoid arthritis
por: Gehin, Johanna Elin, et al.
Publicado: (2021)

A high serum level of eotaxin (CCL 11) is associated with less radiographic progression in early rheumatoid arthritis patients
por: Syversen, Silje W, et al.
Publicado: (2008)

Titers of antibodies against ancestral SARS-CoV-2 correlate with levels of neutralizing antibodies to multiple variants
por: Tran, Trung The, et al.
Publicado: (2022)

Author Correction: Titers of antibodies against ancestral SARS-CoV-2 correlate with levels of neutralizing antibodies to multiple variants
por: Tran, Trung The, et al.
Publicado: (2023)

Therapeutic drug monitoring of infliximab compared to standard clinical treatment with infliximab: study protocol for a randomised, controlled, open, parallel-group, phase IV study (the NOR-DRUM study)
por: Syversen, Silje W, et al.
Publicado: (2020)

The Specificity of Targeted Vaccines for APC Surface Molecules Influences the Immune Response Phenotype
por: Grødeland, Gunnveig, et al.
Publicado: (2013)

Serious infections in patients with rheumatoid arthritis and psoriatic arthritis treated with tumour necrosis factor inhibitors: data from register linkage of the NOR-DMARD study
por: Christensen, Ingrid Egeland, et al.
Publicado: (2022)

Pandemic Preparedness Against Influenza: DNA Vaccine for Rapid Relief
por: Andersen, Tor Kristian, et al.
Publicado: (2021)

Immune responses in Omicron SARS-CoV-2 breakthrough infection in vaccinated adults
por: Kared, Hassen, et al.
Publicado: (2022)

Course and predictors of work productivity in gout — results from the NOR-Gout longitudinal 2-year treat-to-target study
por: Uhlig, Till, et al.
Publicado: (2023)

The Impact of Newer Biological Disease Modifying Anti-Rheumatic Drugs on Cardiovascular Risk Factors: A 12-Month Longitudinal Study in Rheumatoid Arthritis Patients Treated with Rituximab, Abatacept and Tociliziumab
por: Provan, Sella Aarrestad, et al.
Publicado: (2015)

Humoral vaccine response and breakthrough infections in kidney transplant recipients during the COVID-19 pandemic: a nationwide cohort study
por: Hovd, Markus, et al.
Publicado: (2023)

Polarizing T and B Cell Responses by APC-Targeted Subunit Vaccines
por: Grødeland, Gunnveig, et al.
Publicado: (2015)

Urate crystal deposition is associated with inflammatory markers and carotid artery pathology in patients with intercritical gout: results from the NOR-Gout study
por: Hammer, Hilde Berner, et al.
Publicado: (2022)

Determinants of humoral and cellular immune responses to three doses of mRNA SARS-CoV-2 vaccines in older adults: a longitudinal cohort study
por: Ravussin, Anthony, et al.
Publicado: (2023)

Immunogenicity and Safety of a Third SARS-CoV-2 Vaccine Dose in Patients With Multiple Sclerosis and Weak Immune Response After COVID-19 Vaccination
por: König, Marton, et al.
Publicado: (2022)

Immune complexes, innate immunity, and NETosis in ChAdOx1 vaccine-induced thrombocytopenia
por: Holm, Sverre, et al.
Publicado: (2021)

Identification of SNPs associated with methotrexate treatment outcomes in patients with early rheumatoid arthritis
por: Kolan, Shrikant S., et al.
Publicado: (2022)

Lifestyle factors predict gout outcomes: Results from the NOR-Gout longitudinal 2-year treat-to-target study
por: Uhlig, Till, et al.
Publicado: (2023)

The association between disease activity and NT-proBNP in 238 patients with rheumatoid arthritis: a 10-year longitudinal study
por: Provan, Sella A, et al.
Publicado: (2008)

Rheumatoid factor and falsely elevated results in commercial immunoassays: data from an early arthritis cohort
por: Gehin, Johanna E., et al.
Publicado: (2021)

Ejection Time-Corrected Systolic Velocity Improves Accuracy in the Evaluation of Myocardial Dysfunction: A Study in Piglets
por: Odland, Hans Henrik, et al.
Publicado: (2010)

Matrix M Adjuvanted H5N1 Vaccine Elicits Broadly Neutralizing Antibodies and Neuraminidase Inhibiting Antibodies in Humans That Correlate With In Vivo Protection
por: Zhou, Fan, et al.
Publicado: (2021)

Trends in seroprevalence of SARS‐CoV‐2 and infection fatality rate in the Norwegian population through the first year of the COVID‐19 pandemic
por: Tunheim, Gro, et al.
Publicado: (2021)

Humoral immunity to SARS-CoV-2 mRNA vaccination in multiple sclerosis: the relevance of time since last rituximab infusion and first experience from sporadic revaccinations
por: König, Marton, et al.
Publicado: (2023)

A DNA Vaccine That Targets Hemagglutinin to Antigen-Presenting Cells Protects Mice against H7 Influenza
por: Andersen, Tor Kristian, et al.
Publicado: (2017)

Trimeric, APC-Targeted Subunit Vaccines Protect Mice against Seasonal and Pandemic Influenza
por: Tjärnhage, Elias, et al.
Publicado: (2023)

Prevalence of antibodies against SARS‐CoV‐2 in the Norwegian population, August 2021
por: Tunheim, Gro, et al.
Publicado: (2022)

Robust spike-specific CD4(+) and CD8(+) T cell responses in SARS-CoV-2 vaccinated hematopoietic cell transplantation recipients: a prospective, cohort study
por: Federico, Lorenzo, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_kh9ro0a9c42b9latoed95nc8d6